While ADEP tar­gets MRSA, Lewis’ team believes sim­ilar com­pounds will be useful for treating other infec­tions as well as any other dis­ease model that can only be over­come by elim­i­nating a pop­u­la­tion of rogue cells, including can­cerous tumors. They are pur­suing sev­eral already.

NIAID funds basic and translational research with the ultimate goal to develop and promote enhanced diagnostics, better therapeutic treatments, and new vaccines that are effective against

MRSA.

Drs. Michael Otto and Frank DeLeo and their colleagues at the NIAID Rocky Mountain Laboratories recently described the essential role of the phenol-soluble modulin (PSM) protein family in CA-MRSA disease severity